N/A N=104 Physical Activity and Participation
Type 2 Diabetes Mellitus
Primary: Physical Activity — 401.88; -263.81 KCal/week — p==0.18
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=12 Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)
Hereditary Angioedema (HAE)
Primary: Number of Participants Achieving Attack-Free Status for the Efficacy Evaluation Period of Day 0 Through Day 182 — 5 Participants
Phase 3 N=401 Corticosteroid Lumbar Epidural Analgesia for Radiculopathy
Lumbosacral Radicular Pain
Primary: Mean Change From Baseline (Day 1) to Week 4 in the Mean Numeric Pain Rating Scale (NPRS) Average Pain Score in the Affected Leg — -2.34; -1.16 Change in score on a scale…
Phase 3 N=709 ACT-293987 in Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) up to 3 Days After Study Intervention Discontinuation — 684 Participants
N/A N=246 P3 (Prepared, Protected, emPowered)
Sexually Transmitted Diseases · Safe Sex · Adherence, Medication
Primary: PrEP Adherence Defined by Tenofovir Diphosphate (P3 and P3+ vs Control) — 24; 33; 23; 18 Participants — p=0.04965
N/A N=24 Noninvasive Vagus Nerve Stimulation (VNS) for Neuromotor Adaptations
Healthy Young Adults
Primary: Visuomotor Skill — 1; 1; 0.870; 0.969 Ratio of the baseline value — p=0.0096
N/A N=31 High Velocity Nasal Insufflation (Hi-VNI) Use in Upper Airway Surgery
Upper Airway Surgery
Primary: Surgical Case Completion Rate Using HVNI With or Without Converting to Alternative Mode of Oxygenation — 19; 7; 5 Participants
Phase 3 N=672 Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)
HIV Infection
Primary: Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) ≥50 Copies/mL at Week 48 — 0.0; 1.5 Percentage of Participants — p=<.001
Phase 1 N=30 Auditory Training and Hearing Aid Satisfaction
Hearing Impairment, Sensorineural
Primary: Change in Hearing Aid Satisfaction After Auditory Training — 1.9; 1.7 units on a scale — p==0.269
N/A N=23 Virtual Reality After Pediatric Scoliosis Surgery
Scoliosis Idiopathic · Pain, Postoperative
Primary: Pain Scores Via FACES Scale by Patient at Baseline — 0.91; 0.92 score on a scale
N/A N=47 Synchronized Cardiac Assist for Cardiogenic Shock
Shock, Cardiogenic · High Risk Percutaneous Coronary Interventions
Primary: Number of Participants With Device and Procedure Related Serious Adverse Events — 11; 5 Participants
N/A N=16,388 Alinity s Anti-HCV II - Clinical Evaluation Protocol
Healthy
Primary: Assay Specificity Results for Participants (Specimens) Tested With Alinity s Anti-HCV II Assay. — 15,506; 6; 14 Specimen
Phase 2 N=51 Medication Development in Alcoholism: Apremilast Versus Placebo
Alcohol Use Disorder
Primary: Craving to Drink — 33.84; 28.31 score on a scale — p=0.36
Phase 3 N=372 Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris
Acne Vulgaris
Primary: Number of Participants With Treatment RelatedAdverse Events — 10; 9; 0; 0 Participants
Phase 3 N=445 Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 — 10.8; 33.2 percentage of…